Before new drugs are approved for use, they go through a multi-step approval procedure. In recent years, the process has become more globalized, but a new study suggests that the results of clinical trials in one country or region may not be relevant for patients in another. For many new drugs, the biggest market may be in Europe and North America, but when the testing moves out of the lab and into human subjects, increasingly the venues include low- and middle-income countries.
